Petra Klose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Petra Klose has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Winfried Häuser
Klinik für Psychosomatische Medizin und Psychotherapie, Johannes-Gutenberg Universität Mainz, Mainz, Deutschland
22 shared publications - Romy Lauche
National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia, scu.edu.au
18 shared publications Gustav Dobos
A Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine , University of Duisburg-Essen , Essen , Germany
15 shared publications- Holger Cramer
Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany
14 shared publications - Jost Langhorst
Department of Integrative Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany
14 shared publications Jost Langhorst
Department of Integrative Gastroenterology, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Am Deimelsberg 34a, Essen, Germany, 45276
9 shared publications
Latest Publications
- 1 October 2019
- Published by Springer Nature in Deutsche Zeitschrift für Akupunktur
- Vol. 62 (4) , 243-244
Ohrakupunktur bei chronischem Rückenschmerz
- 1 October 2019
- Published by Springer Nature in Deutsche Zeitschrift für Akupunktur
- Vol. 62 (4) , 243-244
Ohrakupunktur bei chronischem Rückenschmerz
- Top Cited PapersOpen Access
- 7 July 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (12) , 1665-1676
Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis
Background: The aim of this meta-analysis was to systematically update the evidence for mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) in women with breast cancer. Material and methods: In October 2016, PubMed, Scopus, and Central were searched for randomized controlled trials on MBSR/MBCT in breast cancer patients. The primary outcome was health-related quality of life. Secondary outcomes were fatigue, sleep stress, depression, anxiety, and safety. For each outcome, standardized mean differences (SMD/Hedges’ g) and 95% confidence intervals (CI) were calculated. Risk of bias was assessed by the Cochrane risk of bias tool. Results: The Literature search identified 14 articles on 10 studies that included 1709 participants. The overall risk of bias was unclear, except for risk of low attrition bias and low other bias. Compared to usual care, significant post-intervention effects of MBSR/MBCT were found for health-related quality of life (SMD = .21; 95%CI = [.04–.39]), fatigue (SMD = −.28; 95%CI = [−.43 to −.14]), sleep (SMD = −.23; 95%CI = [−.40 to −.05]), stress (SMD = −.33; 95%CI = [−.61 to −.05]), anxiety (SMD = −.28; 95%CI = [−.39 to −.16]), and depression (SMD = −.34; 95%CI = [−.46 to −.21]). Up to 6 months after baseline effects were significant for: anxiety (SMD = −.28; 95%CI = [−.47 to −.09]) and depression (SMD = −.26; 95%CI = [−.47 to −.04]); and significant for anxiety (SMD = −.21; 95%CI = [−.40 to −.03]) up to 12 months after baseline. Compared to other active interventions, significant effects were only found post-intervention and only for anxiety (SMD = −.45; 95%CI = [−.71 to −.18]) and depression (SMD = −.39; 95%CI = [−.65 to −.14]). However, average effects were all below the threshold of minimal clinically important differences. Effects were robust against potential methodological bias. Adverse events were insufficiently reported. Conclusions: This meta-analysis revealed evidence for the short-term effectiveness and safety of mindfulness-based interventions in women with breast cancer. However, their clinical relevance remains unclear. Further research is needed.
- 7 July 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (12) , 1665-1676
Top Cited PapersOpen AccessMindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis
Background: The aim of this meta-analysis was to systematically update the evidence for mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) in women with breast cancer. Material and methods: In October 2016, PubMed, Scopus, and Central were searched for randomized controlled trials on MBSR/MBCT in breast cancer patients. The primary outcome was health-related quality of life. Secondary outcomes were fatigue, sleep stress, depression, anxiety, and safety. For each outcome, standardized mean differences (SMD/Hedges’ g) and 95% confidence intervals (CI) were calculated. Risk of bias was assessed by the Cochrane risk of bias tool. Results: The Literature search identified 14 articles on 10 studies that included 1709 participants. The overall risk of bias was unclear, except for risk of low attrition bias and low other bias. Compared to usual care, significant post-intervention effects of MBSR/MBCT were found for health-related quality of life (SMD = .21; 95%CI = [.04–.39]), fatigue (SMD = −.28; 95%CI = [−.43 to −.14]), sleep (SMD = −.23; 95%CI = [−.40 to −.05]), stress (SMD = −.33; 95%CI = [−.61 to −.05]), anxiety (SMD = −.28; 95%CI = [−.39 to −.16]), and depression (SMD = −.34; 95%CI = [−.46 to −.21]). Up to 6 months after baseline effects were significant for: anxiety (SMD = −.28; 95%CI = [−.47 to −.09]) and depression (SMD = −.26; 95%CI = [−.47 to −.04]); and significant for anxiety (SMD = −.21; 95%CI = [−.40 to −.03]) up to 12 months after baseline. Compared to other active interventions, significant effects were only found post-intervention and only for anxiety (SMD = −.45; 95%CI = [−.71 to −.18]) and depression (SMD = −.39; 95%CI = [−.65 to −.14]). However, average effects were all below the threshold of minimal clinically important differences. Effects were robust against potential methodological bias. Adverse events were insufficiently reported. Conclusions: This meta-analysis revealed evidence for the short-term effectiveness and safety of mindfulness-based interventions in women with breast cancer. However, their clinical relevance remains unclear. Further research is needed.
- 1 March 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Komplementärmedizin
- Vol. 09 (02) , 51-53
Naturheilkunde und Komplementäre Verfahren in der nationalen Versorgungsleitlinie „Nicht-spezifischer Kreuzschmerz“
Summary: Unter der Einbindung der Task Force „Naturheilkunde und Komplementärmedizin in Medizinischen Leitlinien“ wurde anhand einer systematischen Literaturrecherche die Evidenzlage für komplementäre Methoden in der aktualisierten Version der Leitlinie „Nicht spezifischer Kreuzschmerz“ neu bewertet, in die Leitlinienkonferenz eingebracht und in den Leitlinien implementiert.Die stärkste positive Empfehlung erhielt die Bewegungstherapie. Es werden ausdrücklich meditative Bewegungsformen wie Yoga, Tai-Chi und die Alexander-Technik empfohlen. Positive Bewertungen werden zudem ausgesprochen für Akupunktur, Progressive Muskelrelaxation und Mobilisation / Manipulation. Die Phytotherapie wird differenziert bewertet, und für einige Phytotherapeutika positive Bewertungen ausgesprochen.
- 1 March 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Komplementärmedizin
- Vol. 09 (02) , 51-53
Naturheilkunde und Komplementäre Verfahren in der nationalen Versorgungsleitlinie „Nicht-spezifischer Kreuzschmerz“
Summary: Unter der Einbindung der Task Force „Naturheilkunde und Komplementärmedizin in Medizinischen Leitlinien“ wurde anhand einer systematischen Literaturrecherche die Evidenzlage für komplementäre Methoden in der aktualisierten Version der Leitlinie „Nicht spezifischer Kreuzschmerz“ neu bewertet, in die Leitlinienkonferenz eingebracht und in den Leitlinien implementiert.Die stärkste positive Empfehlung erhielt die Bewegungstherapie. Es werden ausdrücklich meditative Bewegungsformen wie Yoga, Tai-Chi und die Alexander-Technik empfohlen. Positive Bewertungen werden zudem ausgesprochen für Akupunktur, Progressive Muskelrelaxation und Mobilisation / Manipulation. Die Phytotherapie wird differenziert bewertet, und für einige Phytotherapeutika positive Bewertungen ausgesprochen.
- Top Cited Papers
- 3 January 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (1) , CD010802
Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer
Breast cancer is the cancer most frequently diagnosed in women worldwide. Even though survival rates are continually increasing, breast cancer is often associated with long-term psychological distress, chronic pain, fatigue and impaired quality of life. Yoga comprises advice for an ethical lifestyle, spiritual practice, physical activity, breathing exercises and meditation. It is a complementary therapy that is commonly recommended for breast cancer-related impairments and has been shown to improve physical and mental health in people with different cancer types. To assess effects of yoga on health-related quality of life, mental health and cancer-related symptoms among women with a diagnosis of breast cancer who are receiving active treatment or have completed treatment. We searched the Cochrane Breast Cancer Specialised Register, MEDLINE (via PubMed), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), Indexing of Indian Medical Journals (IndMED), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal and Clinicaltrials.gov on 29 January 2016. We also searched reference lists of identified relevant trials or reviews, as well as conference proceedings of the International Congress on Complementary Medicine Research (ICCMR), the European Congress for Integrative Medicine (ECIM) and the American Society of Clinical Oncology (ASCO). We applied no language restrictions. Randomised controlled trials were eligible when they (1) compared yoga interventions versus no therapy or versus any other active therapy in women with a diagnosis of non-metastatic or metastatic breast cancer, and (2) assessed at least one of the primary outcomes on patient-reported instruments, including health-related quality of life, depression, anxiety, fatigue or sleep disturbances. Two review authors independently collected data on methods and results. We expressed outcomes as standardised mean differences (SMDs) with 95% confidence intervals (CIs) and conducted random-effects model meta-analyses. We assessed potential risk of publication bias through visual analysis of funnel plot symmetry and heterogeneity between studies by using the Chi2 test and the I2 statistic. We conducted subgroup analyses for current treatment status, time since diagnosis, stage of cancer and type of yoga intervention. We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.
- 3 January 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (1) , CD010802
Top Cited PapersYoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer
Breast cancer is the cancer most frequently diagnosed in women worldwide. Even though survival rates are continually increasing, breast cancer is often associated with long-term psychological distress, chronic pain, fatigue and impaired quality of life. Yoga comprises advice for an ethical lifestyle, spiritual practice, physical activity, breathing exercises and meditation. It is a complementary therapy that is commonly recommended for breast cancer-related impairments and has been shown to improve physical and mental health in people with different cancer types. To assess effects of yoga on health-related quality of life, mental health and cancer-related symptoms among women with a diagnosis of breast cancer who are receiving active treatment or have completed treatment. We searched the Cochrane Breast Cancer Specialised Register, MEDLINE (via PubMed), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), Indexing of Indian Medical Journals (IndMED), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal and Clinicaltrials.gov on 29 January 2016. We also searched reference lists of identified relevant trials or reviews, as well as conference proceedings of the International Congress on Complementary Medicine Research (ICCMR), the European Congress for Integrative Medicine (ECIM) and the American Society of Clinical Oncology (ASCO). We applied no language restrictions. Randomised controlled trials were eligible when they (1) compared yoga interventions versus no therapy or versus any other active therapy in women with a diagnosis of non-metastatic or metastatic breast cancer, and (2) assessed at least one of the primary outcomes on patient-reported instruments, including health-related quality of life, depression, anxiety, fatigue or sleep disturbances. Two review authors independently collected data on methods and results. We expressed outcomes as standardised mean differences (SMDs) with 95% confidence intervals (CIs) and conducted random-effects model meta-analyses. We assessed potential risk of publication bias through visual analysis of funnel plot symmetry and heterogeneity between studies by using the Chi2 test and the I2 statistic. We conducted subgroup analyses for current treatment status, time since diagnosis, stage of cancer and type of yoga intervention. We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.
- 13 December 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (6) , 370-372
Rehabilitation, Physikalische Medizin und Naturheilverfahren: Stand der Lehre im QB12 an deutschen Medizinischen Fakultäten
- 13 December 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (6) , 370-372
Rehabilitation, Physikalische Medizin und Naturheilverfahren: Stand der Lehre im QB12 an deutschen Medizinischen Fakultäten
- 1 December 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 37 (06) , 242-247
Phytotherapy for osteoarthritis
Background: In order to present recent findings on the effectiveness and safety of phytotherapy for treatment of osteoarthritis (OA) we summarized the two latest Cochrane reviews (Cameron & Chrubasik, 2013; Cameron & Chrubasik, 2014). One of them included oral and the other topical herbal treatment options as a treatment for OA. Methods: We conducted a thorough evaluation of the Cochrane reviews. We assessed methodological quality of the reviews and extracted evidence. Results: Meta-analyses found evidence for effects of the oral herbal products Boswellia serrata and only partially for avocado-soybean unsaponifiable (ASU). However, they included only a small number of primary studies. The systematic review on topical herbal treatments included fewer trials and did not include a meta-analysis. Discussion: Based on the qualitative synthesis Boswellia serrata can be applied in the treatment of OA. It is not clear if ASU can be recommended. No valid recommendation can be given for or against other herbal therapies due to a lack of randomized clinical trials in the field. Phytotherapie bei Arthrose: Evidenz zweier Cochrane-Reviews Hintergrund: Um aktuelle Erkenntnisse über Wirksamkeit und Sicherheit von phytotherapeutischen Präparaten bei der Behandlung von Osteoarthritis (OA) zu erlangen, wurden die beiden neuesten Cochrane-Reviews (Cameron & Chrubasik, 2013; Cameron & Chrubasik, 2014) zusammengefasst. Ein Review befasste sich mit oralen und der andere mit topisch-pflanzlichen Behandlungsmöglichkeiten bei OA. Methodik: Es wurde eine gründliche Bewertung der beiden Cochrane-Reviews durchgeführt. Wir beurteilten die methodische Qualität der Bewertungen und leiteten daraus Aussagen zur Evidenz ab. Ergebnisse: Die Metaanalysen offenbarten Nachweise für die Wirkung der oralen Boswellia-serrata-Produkte sowie der teilweisen Wirksamkeit der Avocado-Soja (ASU)-Präparate. Die Primärstudien enthielten jedoch nur eine kleine Anzahl von Stichproben. Die systematische Überprüfung der topisch-pyhtotherapeutischen Produkte enthielt nur wenige klinische Studien und beinhaltete keine Metaanalyse. Schlussfolgerung: Basierend auf der qualitativen Synthese kann eine Behandlung von OA mit Boswellia-serrata-Präparaten empfohlen werden. Zur Anwendung von ASU liegt nur unzureichende Evidenz hinsichtlich der Wirksamkeit vor. Aufgrund mangelnder randomisierter klinischer Studien kann keine gültige Empfehlung für oder gegen andere pflanzliche Präparate gegeben werden.
- 1 December 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 37 (06) , 242-247
Phytotherapy for osteoarthritis
Background: In order to present recent findings on the effectiveness and safety of phytotherapy for treatment of osteoarthritis (OA) we summarized the two latest Cochrane reviews (Cameron & Chrubasik, 2013; Cameron & Chrubasik, 2014). One of them included oral and the other topical herbal treatment options as a treatment for OA. Methods: We conducted a thorough evaluation of the Cochrane reviews. We assessed methodological quality of the reviews and extracted evidence. Results: Meta-analyses found evidence for effects of the oral herbal products Boswellia serrata and only partially for avocado-soybean unsaponifiable (ASU). However, they included only a small number of primary studies. The systematic review on topical herbal treatments included fewer trials and did not include a meta-analysis. Discussion: Based on the qualitative synthesis Boswellia serrata can be applied in the treatment of OA. It is not clear if ASU can be recommended. No valid recommendation can be given for or against other herbal therapies due to a lack of randomized clinical trials in the field. Phytotherapie bei Arthrose: Evidenz zweier Cochrane-Reviews Hintergrund: Um aktuelle Erkenntnisse über Wirksamkeit und Sicherheit von phytotherapeutischen Präparaten bei der Behandlung von Osteoarthritis (OA) zu erlangen, wurden die beiden neuesten Cochrane-Reviews (Cameron & Chrubasik, 2013; Cameron & Chrubasik, 2014) zusammengefasst. Ein Review befasste sich mit oralen und der andere mit topisch-pflanzlichen Behandlungsmöglichkeiten bei OA. Methodik: Es wurde eine gründliche Bewertung der beiden Cochrane-Reviews durchgeführt. Wir beurteilten die methodische Qualität der Bewertungen und leiteten daraus Aussagen zur Evidenz ab. Ergebnisse: Die Metaanalysen offenbarten Nachweise für die Wirkung der oralen Boswellia-serrata-Produkte sowie der teilweisen Wirksamkeit der Avocado-Soja (ASU)-Präparate. Die Primärstudien enthielten jedoch nur eine kleine Anzahl von Stichproben. Die systematische Überprüfung der topisch-pyhtotherapeutischen Produkte enthielt nur wenige klinische Studien und beinhaltete keine Metaanalyse. Schlussfolgerung: Basierend auf der qualitativen Synthese kann eine Behandlung von OA mit Boswellia-serrata-Präparaten empfohlen werden. Zur Anwendung von ASU liegt nur unzureichende Evidenz hinsichtlich der Wirksamkeit vor. Aufgrund mangelnder randomisierter klinischer Studien kann keine gültige Empfehlung für oder gegen andere pflanzliche Präparate gegeben werden.
- 18 July 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (8) , CD011694
Cannabinoids for fibromyalgia
This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue affecting approximately 2% of the general population. People often report high disability levels and poor health-related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Cannabis has been used for millennia to reduce pain and other somatic and psychological symptoms. To assess the efficacy, tolerability and safety of cannabinoids for fibromyalgia symptoms in adults. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to April 2016, together with reference lists of retrieved papers and reviews, three clinical trial registries, and contact with trial authors. We selected randomised controlled trials of at least four weeks' duration of any formulation of cannabis products used for the treatment of adults with fibromyalgia. Two review authors independently extracted the data of all included studies and assessed risk of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. First tier evidence was derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for drop-outs; at least 200 participants in the comparison, eight to 12 weeks' duration, parallel design), second tier evidence from data that did not meet one or more of these criteria and were considered at some risk of bias but with adequate numbers (i.e. data from at least 200 participants) in the comparison, and third tier evidence from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation). We included two studies with 72 participants. Overall, the two studies were at moderate risk of bias. The evidence was derived from group mean data and completer analysis (very low quality evidence overall). We rated the quality of all outcomes according to GRADE as very low due to indirectness, imprecision and potential reporting bias. The primary outcomes in our review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Nabilone was compared to placebo and to amitriptyline in one study each. Study sizes were 32 and 40 participants. One study used a cross-over design and one used a parallel group design; study duration was four or six weeks. Both studies used nabilone, a synthetic cannabinoid, with a bedtime dosage of 1 mg/day. No study reported the proportion of participants experiencing at least 30% or 50% pain relief or who were very much improved. No study provided first or second tier (high to moderate quality) evidence for an outcome of efficacy, tolerability and safety. Third tier (very low quality) evidence indicated greater reduction of pain and limitations of HRQoL compared to placebo in one study. There were no significant differences to placebo noted for fatigue and depression (very low quality evidence). Third tier evidence indicated better effects of nabilone on sleep than amitriptyline (very low quality evidence). There were no significant differences between the two drugs noted for pain, mood and HRQoL (very low quality evidence). More participants dropped out due to adverse events in the nabilone groups (4/52 participants) than in the control groups (1/20 in placebo and 0/32 in amitriptyline group). The most frequent adverse events were dizziness, nausea, dry mouth and drowsiness (six participants with nabilone). Neither study reported serious adverse events during the period of both studies. We planned to create a GRADE 'Summary of findings' table, but due to the scarcity of data we were unable to do this. We found no relevant study with herbal cannabis, plant-based cannabinoids or synthetic cannabinoids other than nabilone in fibromyalgia. We found no convincing, unbiased, high quality evidence suggesting that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia.
- 18 July 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (8) , CD011694
Cannabinoids for fibromyalgia
This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue affecting approximately 2% of the general population. People often report high disability levels and poor health-related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Cannabis has been used for millennia to reduce pain and other somatic and psychological symptoms. To assess the efficacy, tolerability and safety of cannabinoids for fibromyalgia symptoms in adults. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to April 2016, together with reference lists of retrieved papers and reviews, three clinical trial registries, and contact with trial authors. We selected randomised controlled trials of at least four weeks' duration of any formulation of cannabis products used for the treatment of adults with fibromyalgia. Two review authors independently extracted the data of all included studies and assessed risk of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. First tier evidence was derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for drop-outs; at least 200 participants in the comparison, eight to 12 weeks' duration, parallel design), second tier evidence from data that did not meet one or more of these criteria and were considered at some risk of bias but with adequate numbers (i.e. data from at least 200 participants) in the comparison, and third tier evidence from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation). We included two studies with 72 participants. Overall, the two studies were at moderate risk of bias. The evidence was derived from group mean data and completer analysis (very low quality evidence overall). We rated the quality of all outcomes according to GRADE as very low due to indirectness, imprecision and potential reporting bias. The primary outcomes in our review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Nabilone was compared to placebo and to amitriptyline in one study each. Study sizes were 32 and 40 participants. One study used a cross-over design and one used a parallel group design; study duration was four or six weeks. Both studies used nabilone, a synthetic cannabinoid, with a bedtime dosage of 1 mg/day. No study reported the proportion of participants experiencing at least 30% or 50% pain relief or who were very much improved. No study provided first or second tier (high to moderate quality) evidence for an outcome of efficacy, tolerability and safety. Third tier (very low quality) evidence indicated greater reduction of pain and limitations of HRQoL compared to placebo in one study. There were no significant differences to placebo noted for fatigue and depression (very low quality evidence). Third tier evidence indicated better effects of nabilone on sleep than amitriptyline (very low quality evidence). There were no significant differences between the two drugs noted for pain, mood and HRQoL (very low quality evidence). More participants dropped out due to adverse events in the nabilone groups (4/52 participants) than in the control groups (1/20 in placebo and 0/32 in amitriptyline group). The most frequent adverse events were dizziness, nausea, dry mouth and drowsiness (six participants with nabilone). Neither study reported serious adverse events during the period of both studies. We planned to create a GRADE 'Summary of findings' table, but due to the scarcity of data we were unable to do this. We found no relevant study with herbal cannabis, plant-based cannabinoids or synthetic cannabinoids other than nabilone in fibromyalgia. We found no convincing, unbiased, high quality evidence suggesting that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia.
- 23 June 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (3) , 165-169
A Systematic Review of Phytotherapy for Acute Rhinosinusitis
Herbal medicine is a promising alternative in the treatment of acute rhinosinusitis (ARS). We performed a systematic review for phytopharmaceutical treatments of ARS. A computerized search of databases (Cochrane Library, PubMed, and Scopus) up to 16 September 2015 was performed. Randomized controlled trials (RCTs) and controlled trials (CTs) were included and assessed using the Cochrane risk of bias tool. Seven trials on Pelargonium sidoides (EPs 7630, Umckaloabo®), Myrtol (GeloMyrtol® forte), BNO 1016 (Sinupret® extract), BNO 101 (Sinupret®), Cyclamen europaeum (Nasodren®), and Esberitox® were included. Risk of bias was heterogeneous. EPs 7630 appeared to be useful in the treatment of ARS. Myrtol showed benefits against a placebo compound, and BNO 1016 and BNO 101 might be helpful; however, there was little evidence for the effectiveness of Cyclamen europaeum and Esberitox®. Herbal medicine might be effective for the treatment of ARS, but given the low number of clinical trials and the heterogeneous methodological quality, further research is necessary.
- 23 June 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (3) , 165-169
A Systematic Review of Phytotherapy for Acute Rhinosinusitis
Herbal medicine is a promising alternative in the treatment of acute rhinosinusitis (ARS). We performed a systematic review for phytopharmaceutical treatments of ARS. A computerized search of databases (Cochrane Library, PubMed, and Scopus) up to 16 September 2015 was performed. Randomized controlled trials (RCTs) and controlled trials (CTs) were included and assessed using the Cochrane risk of bias tool. Seven trials on Pelargonium sidoides (EPs 7630, Umckaloabo®), Myrtol (GeloMyrtol® forte), BNO 1016 (Sinupret® extract), BNO 101 (Sinupret®), Cyclamen europaeum (Nasodren®), and Esberitox® were included. Risk of bias was heterogeneous. EPs 7630 appeared to be useful in the treatment of ARS. Myrtol showed benefits against a placebo compound, and BNO 1016 and BNO 101 might be helpful; however, there was little evidence for the effectiveness of Cyclamen europaeum and Esberitox®. Herbal medicine might be effective for the treatment of ARS, but given the low number of clinical trials and the heterogeneous methodological quality, further research is necessary.
- 23 June 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (3) , 154-164
Berücksichtigung von Wechsel- und Nebenwirkungen bei pflanzlichen Arzneimitteln in deutschen S3-Leitlinien der AWMF
Pflanzliche Arzneimittel haben in der medizinischen Versorgung im deutschsprachigen Raum eine lange Tradition, werden aber bei der Erstellung medizinischer Leitlinien selten berücksichtigt. In einer Vorstudie wurde von unserer Arbeitsgruppe aufgearbeitet, in welchem Ausmaß sie in den aktuellen interdisziplinär, evidenz- und konsensusbasiert erstellten S3-Leitlinien der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Beachtung gefunden haben. Ziel der jetzigen Studie war es, zu analysieren, inwieweit Neben- bzw. Wechselwirkungen von pflanzlichen Arzneimitteln in diesen S3-Leitlinien diskutiert werden. Im Januar 2015 wurden 134 S3-Leitlinien gezählt und analysiert. 27,6% (n = 37) weisen insgesamt 194 Statements unter dem Begriff «Phytotherapie» auf. Hinweise zu Neben- und Wechselwirkungen finden sich in 28,4% der Statements (n = 55), die bei 13,9% (n = 27) durch Literatur belegt werden. 14 dieser Statements betreffen Nahrungsergänzungsmittel und Ähnliches, 11 sind pauschale Aussagen zur Phytotherapie, 7 fassen mindestens 2 Arzneipflanzen pauschal zusammen. Damit weisen nur 23 Statements auf Neben- bzw. Wechselwirkungen von einzelnen Arzneipflanzen hin, 14 davon sind mit Literaturstellen belegt. Diese Ergebnisse entsprechen bei Weitem nicht den geforderten Standards der AWMF. Dafür verantwortlich sind insbesondere unpräzise Begrifflichkeiten sowie eine unzureichende Systematik bei der Suche nach wissenschaftlicher Evidenz für die Unbedenklichkeit von Arzneipflanzen-Zubereitungen. Die Gesellschaft für Phytotherapie kann hier einen wichtigen Beitrag zur Qualitätsverbesserung leisten.
- 23 June 2016
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 23 (3) , 154-164
Berücksichtigung von Wechsel- und Nebenwirkungen bei pflanzlichen Arzneimitteln in deutschen S3-Leitlinien der AWMF
Pflanzliche Arzneimittel haben in der medizinischen Versorgung im deutschsprachigen Raum eine lange Tradition, werden aber bei der Erstellung medizinischer Leitlinien selten berücksichtigt. In einer Vorstudie wurde von unserer Arbeitsgruppe aufgearbeitet, in welchem Ausmaß sie in den aktuellen interdisziplinär, evidenz- und konsensusbasiert erstellten S3-Leitlinien der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Beachtung gefunden haben. Ziel der jetzigen Studie war es, zu analysieren, inwieweit Neben- bzw. Wechselwirkungen von pflanzlichen Arzneimitteln in diesen S3-Leitlinien diskutiert werden. Im Januar 2015 wurden 134 S3-Leitlinien gezählt und analysiert. 27,6% (n = 37) weisen insgesamt 194 Statements unter dem Begriff «Phytotherapie» auf. Hinweise zu Neben- und Wechselwirkungen finden sich in 28,4% der Statements (n = 55), die bei 13,9% (n = 27) durch Literatur belegt werden. 14 dieser Statements betreffen Nahrungsergänzungsmittel und Ähnliches, 11 sind pauschale Aussagen zur Phytotherapie, 7 fassen mindestens 2 Arzneipflanzen pauschal zusammen. Damit weisen nur 23 Statements auf Neben- bzw. Wechselwirkungen von einzelnen Arzneipflanzen hin, 14 davon sind mit Literaturstellen belegt. Diese Ergebnisse entsprechen bei Weitem nicht den geforderten Standards der AWMF. Dafür verantwortlich sind insbesondere unpräzise Begrifflichkeiten sowie eine unzureichende Systematik bei der Suche nach wissenschaftlicher Evidenz für die Unbedenklichkeit von Arzneipflanzen-Zubereitungen. Die Gesellschaft für Phytotherapie kann hier einen wichtigen Beitrag zur Qualitätsverbesserung leisten.
- 2 June 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (9) , CD011804
Antipsychotics for fibromyalgia in adults
This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue. It affects approximately 2% of the general population. Up to 70% of patients with fibromyalgia meet the criteria for a depressive or anxiety disorder. People often report high disability levels and poor health-related quality of life. Drug therapy focuses on reducing key symptoms and disability, and improving health-related quality of life. Antipsychotics might reduce fibromyalgia and associated mental health symptoms. To assess the efficacy, tolerability and safety of antipsychotics in fibromyalgia in adults. We searched CENTRAL (2016, Issue 4), MEDLINE and EMBASE to 20 May 2016, together with reference lists of retrieved papers and reviews and two clinical trial registries. We also contacted trial authors. We selected controlled trials of at least four weeks duration of any formulation of antipsychotics used for the treatment of fibromyalgia in adults. We extracted the data from all included studies and two review authors independently assessed study risks of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. We derived first tier evidence from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for drop-outs, at least 200 participants in the comparison, eight to 12 weeks duration, parallel design), second tier evidence from data that failed to meet one or more of these criteria and that we considered at some risk of bias but with adequate numbers in the comparison, and third tier evidence from data involving small numbers of participants that we considered very likely to be biased or used outcomes of limited clinical utility, or both. We rated the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. We included a total of four studies with 296 participants. Three studies with 206 participants compared quetiapine, an atypical (second-generation) antipsychotic, with placebo. One study used a cross-over design and two studies a parallel-group design. Study duration was eight or 12 weeks. Quetiapine was used in all studies with a bedtime dosage between 50 and 300 mg/day. All studies had one or more sources of potential major bias and we judged them to be at moderate risk of bias overall. The primary outcomes in this review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Second tier evidence indicated that quetiapine was not statistically superior to placebo in the number of participants with a 50% or more pain reduction (very low quality evidence). No study reported data on PGIC. A greater proportion of participants on quetiapine reported a 30% or more pain reduction (risk difference (RD) 0.12, 95% confidence interval (CI) 0.00 to 0.23; number needed to treat for an additional benefit (NNTB) 8, 95% CI 5 to 100) (very low quality evidence). A greater proportion of participants on quetiapine reported a clinically relevant improvement of health-related quality of life compared to placebo ( RD 0.18, 95% CI 0.05 to 0.31; NNTB 5, 95% CI 3 to 20) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing sleep problems (standardised mean difference (SMD) -0.67, 95% CI -1.10 to -0.23), depression (SMD -0.39, 95% CI -0.74 to -0.04) and anxiety (SMD -0.40, 95% CI -0.69 to -0.11) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing the risk of withdrawing from the study due to a lack of efficacy (RD -0.14, 95% CI -0.23 to -0.05) (very low quality evidence). There was no statistically significant difference between quetiapine and placebo in the proportion of participants withdrawing due to adverse events (tolerability) (very low quality evidence), in the frequency of serious adverse events (safety) (very low quality evidence) and in the proportion of participants reporting dizziness and somnolence as an adverse event (very low quality evidence). In more participants in the quetiapine group a substantial weight gain was noted (RD 0.08, 95% CI 0.02 to 0.15; number needed to treat for an additional harm (NNTH) 12, 95% CI 6 to 50) (very low quality evidence). We downgraded the quality of evidence by three levels to a very low quality rating because of limitations of study design, indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). One parallel design study with 90 participants compared quetiapine (50 to 300 mg/day flexible at bedtime) to amitriptyline (10 to 75 mg/day flexible at bedtime). The study had three major risks of bias and we judged it to be at moderate risk of bias overall. We downgraded the quality of evidence by two levels to a low quality rating because of indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). Third tier evidence indicated no statistically significant differences between the two drugs. Both drugs did not statistically significantly differ in the reduction of average scores for pain, fatigue, sleep problems, depression, anxiety and for limitations of health-related quality of life and in the proportion of participants reporting dizziness, somnolence and weight gain as a side effect (low quality evidence). Compared to amitriptyline, more participants left the study due to adverse events (low quality evidence). No serious adverse events were reported (low quality evidence). We found no...
- 2 June 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (9) , CD011804
Antipsychotics for fibromyalgia in adults
This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue. It affects approximately 2% of the general population. Up to 70% of patients with fibromyalgia meet the criteria for a depressive or anxiety disorder. People often report high disability levels and poor health-related quality of life. Drug therapy focuses on reducing key symptoms and disability, and improving health-related quality of life. Antipsychotics might reduce fibromyalgia and associated mental health symptoms. To assess the efficacy, tolerability and safety of antipsychotics in fibromyalgia in adults. We searched CENTRAL (2016, Issue 4), MEDLINE and EMBASE to 20 May 2016, together with reference lists of retrieved papers and reviews and two clinical trial registries. We also contacted trial authors. We selected controlled trials of at least four weeks duration of any formulation of antipsychotics used for the treatment of fibromyalgia in adults. We extracted the data from all included studies and two review authors independently assessed study risks of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. We derived first tier evidence from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for drop-outs, at least 200 participants in the comparison, eight to 12 weeks duration, parallel design), second tier evidence from data that failed to meet one or more of these criteria and that we considered at some risk of bias but with adequate numbers in the comparison, and third tier evidence from data involving small numbers of participants that we considered very likely to be biased or used outcomes of limited clinical utility, or both. We rated the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. We included a total of four studies with 296 participants. Three studies with 206 participants compared quetiapine, an atypical (second-generation) antipsychotic, with placebo. One study used a cross-over design and two studies a parallel-group design. Study duration was eight or 12 weeks. Quetiapine was used in all studies with a bedtime dosage between 50 and 300 mg/day. All studies had one or more sources of potential major bias and we judged them to be at moderate risk of bias overall. The primary outcomes in this review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Second tier evidence indicated that quetiapine was not statistically superior to placebo in the number of participants with a 50% or more pain reduction (very low quality evidence). No study reported data on PGIC. A greater proportion of participants on quetiapine reported a 30% or more pain reduction (risk difference (RD) 0.12, 95% confidence interval (CI) 0.00 to 0.23; number needed to treat for an additional benefit (NNTB) 8, 95% CI 5 to 100) (very low quality evidence). A greater proportion of participants on quetiapine reported a clinically relevant improvement of health-related quality of life compared to placebo ( RD 0.18, 95% CI 0.05 to 0.31; NNTB 5, 95% CI 3 to 20) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing sleep problems (standardised mean difference (SMD) -0.67, 95% CI -1.10 to -0.23), depression (SMD -0.39, 95% CI -0.74 to -0.04) and anxiety (SMD -0.40, 95% CI -0.69 to -0.11) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing the risk of withdrawing from the study due to a lack of efficacy (RD -0.14, 95% CI -0.23 to -0.05) (very low quality evidence). There was no statistically significant difference between quetiapine and placebo in the proportion of participants withdrawing due to adverse events (tolerability) (very low quality evidence), in the frequency of serious adverse events (safety) (very low quality evidence) and in the proportion of participants reporting dizziness and somnolence as an adverse event (very low quality evidence). In more participants in the quetiapine group a substantial weight gain was noted (RD 0.08, 95% CI 0.02 to 0.15; number needed to treat for an additional harm (NNTH) 12, 95% CI 6 to 50) (very low quality evidence). We downgraded the quality of evidence by three levels to a very low quality rating because of limitations of study design, indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). One parallel design study with 90 participants compared quetiapine (50 to 300 mg/day flexible at bedtime) to amitriptyline (10 to 75 mg/day flexible at bedtime). The study had three major risks of bias and we judged it to be at moderate risk of bias overall. We downgraded the quality of evidence by two levels to a low quality rating because of indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). Third tier evidence indicated no statistically significant differences between the two drugs. Both drugs did not statistically significantly differ in the reduction of average scores for pain, fatigue, sleep problems, depression, anxiety and for limitations of health-related quality of life and in the proportion of participants reporting dizziness, somnolence and weight gain as a side effect (low quality evidence). Compared to amitriptyline, more participants left the study due to adverse events (low quality evidence). No serious adverse events were reported (low quality evidence). We found no...